Investment

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 29 May 2025. Alzamend Neuro (NASDAQ: ALZN) reported that the initial subject in the Phase II “Lithium-in-Brain” trial has received its dosage of AL001 for comparison against lithium carbonate. The study’s primary findings are antic Revelation Biosciences (NASDAQ: REVB) priced a US$4m public offering of 3.64m shares (or equivalents) and warrants for up to 14.56m shares at US$1.10 per share and warrant. Warrants are exercisable at US$1.10 upon stoc IMUNON (NASDAQ: IMNN) completed a US$3.25m private placement by selling 7,222,223 common shares and short-term warrants for an additional 14,444,446 shares at US$0.45 per share. The warrants could generate up to US$6.5 Applied DNA Sciences (NASDAQ: APDN) will implement a 1‑for‑15 reverse stock split effective 2 June 2025. Shares closed down 37% at US$0.33. Intensity Therapeutics (NASDAQ: INTS) will showcase a Trials‑in‑Progress poster on its Phase 3 INVINCIBLE‑3 study of intratumoral INT230‑6 in metastatic soft‑tissue sarcoma at ASCO 2025. Shares closed up 34% at US$0.39 ORIC Pharmaceuticals (NASDAQ: ORIC) reported Phase 1b data for ORIC-944 in mCRPC, with 59% PSA50 and 24% PSA90 confirmed response rates. They also secured approximately US$125m via a private placement at US$6.50 per sh Immunic (NASDAQ: IMUX) announced the pricing of a public offering including pre-funded warrants exercisable immediately, Series A warrants exercisable until 31 December 2025, and Series B warrants exercisable starting Intellia Therapeutics (NASDAQ: NTLA) shares are currently down during premarket hours after reporting a Grade 4 liver enzyme elevation in a patient in the late-stage MAGNITUDE trial for its Regeneron (NASDAQ: REGN)-par

V小姐

3 months ago

My MPF Portfolio Outperforms in May

May 2025 proved to be a robust month for my Manulife MPF portfolio, achieving its first outperformance against the overall MPF system since January 2025. A steady rally in US, China, and Japan equities drove my MPF portfolio to a 6.25% gain in May, surpassing the MPFR All Fund Performance Index, whi

Anthony Tran

2 months ago

BYD vs Tesla: A Valuation Approach

Investing in the stock market, very often, doesn’t require an advanced degree in finance or mastery of complex financial models. By applying straightforward logic, anyone can spot opportunities obscured by market storytelling. A direct comparison of the world’s top two electric vehicle (EV) manufact

Anthony Tran

3 months ago